• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Covidien launches 2 trials to support its Stellarex drug-device combo

July 17, 2013 By drugdelivery

Covidien launched 2 trials to support its Stellarex drug-device combo

Covidien (NYSE:COV) kicked off 2 new clinical trials this week to support a global evaluation of its Stellarex drug-coated angioplasty balloon.

The Massachusetts-based company started enrolling patients with peripheral arterial disease in the Pivotal and PK arms of its larger ILLUMENATE clinical trials examining the safety and effectiveness of Covidien’s Stellarex devices.

Both the PK and Pivotal study will evaluate the Stellarex balloon in treatment of de novo blockages or re-blockage of the superficial femoral or popliteal arteries, according to a company press release. The PK study will enroll up to 25 patients, with 1st enrollment taking place in New Zealand. The Pivotal arm will enroll up to 360 patients in the U.S.

Peripheral arterial disease occurs when plaque builds up in the leg arteries, a condition affecting more than 10 million people in the U.S., according to Covidien. The device has not hit shelves in the States, but the FDA granted investigational device exemption so that Covidien can move forward with its clinical trials.

"The ILLUMENATE clinical trial program demonstrates Covidien’s commitment to provide evidence-based treatment options for physicians and their patients who suffer from PAD," said CMO Dr. Mark Turco in prepared remarks. "Robust clinical evidence is critical in enabling physicians to make the best possible treatment decisions and achieving the best outcomes for their patients."

The 2 trials that launched this week are part of a series of 4 trials for Stellarex, including a European trial and a global trial currently enrolling patients.

This month, the company finalized the spin-out of its pharmaceutical business by announcing the launch of Mallinckrodt plc (NYSE:MNK) on the New York Stock Exchange.

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Clinical Trials, Covidien, Peripheral Artery Disease

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS